Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bromocriptine for Risperidone-Induced Hyperprolactinemia
NCT00315081Phase 3Unknown
- Sponsor
- University Hospital Bonn
- Start
- May 2006
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label trial of bromocriptine in hyperprolactinemia, sponsored by University Hospital Bonn. Primary endpoints: Prolactin at 24 weeks and Luteinizing Hormone at 24 weeks. Status: unknown.
02
Drugs
bromocriptine
03
Conditions
hyperprolactinemia
Beyond the preview
Go deeper on NCT00315081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00315081.